Abstract
Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs), decrease the risk of developing Alzheimers disease (AD). Their beneficial effects may be due to interference in the chronic inflammatory reaction, that takes place in AD. The best-characterized action of NSAIDs is the inhibition of cyclooxygenase (COX). There is special interest for anti-inflammatory treatment of AD using selective COX-2 inhibitors. These inhibitors reduce the inflammatory reaction but lack the side effects observed with non-selective NSAIDs. So far, clinical trials designed to inhibit inflammation or COX-2 activity have failed in the treatment of AD patients. Several lines of evidence can explain the failures of the anti-inflammatory and anti-COX-2 trials on AD patients. In this review we will focus on the role, expression and regulation of COX-1 and COX-2 in AD brain. Understanding the role of COX in AD pathogenesis could contribute to the development of an anti-inflammatory therapy for the treatment or prevention of AD.
Keywords: alzheimers disease, cyclooxygenase, inflammation, microglia, neuron, non-steroidal anti-inflammatory drugs
Current Drug Targets
Title: Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer s Disease
Volume: 4 Issue: 6
Author(s): Jeroen J.M. Hoozemans, Robert Veerhuis, Annemieke J.M. Rozemuller and Piet Eikelenboom
Affiliation:
Keywords: alzheimers disease, cyclooxygenase, inflammation, microglia, neuron, non-steroidal anti-inflammatory drugs
Abstract: Epidemiological studies indicate that anti-inflammatory drugs, especially the non-steroidal anti-inflammatory drugs (NSAIDs), decrease the risk of developing Alzheimers disease (AD). Their beneficial effects may be due to interference in the chronic inflammatory reaction, that takes place in AD. The best-characterized action of NSAIDs is the inhibition of cyclooxygenase (COX). There is special interest for anti-inflammatory treatment of AD using selective COX-2 inhibitors. These inhibitors reduce the inflammatory reaction but lack the side effects observed with non-selective NSAIDs. So far, clinical trials designed to inhibit inflammation or COX-2 activity have failed in the treatment of AD patients. Several lines of evidence can explain the failures of the anti-inflammatory and anti-COX-2 trials on AD patients. In this review we will focus on the role, expression and regulation of COX-1 and COX-2 in AD brain. Understanding the role of COX in AD pathogenesis could contribute to the development of an anti-inflammatory therapy for the treatment or prevention of AD.
Export Options
About this article
Cite this article as:
Hoozemans J.M. Jeroen, Veerhuis Robert, Rozemuller J.M. Annemieke and Eikelenboom Piet, Non-steroidal Anti-inflammatory Drugs and Cyclooxygenase in Alzheimer s Disease, Current Drug Targets 2003; 4 (6) . https://dx.doi.org/10.2174/1389450033490902
DOI https://dx.doi.org/10.2174/1389450033490902 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cholinesterases: Roles in the Brain During Health and Disease
Current Alzheimer Research Gene and Cell Therapy for Prion Diseases
Infectious Disorders - Drug Targets Functional Connectivity Hubs Could Serve as a Potential Biomarker in Alzheimer’s Disease: A Reproducible Study
Current Alzheimer Research Older Adults with Amnestic Mild Cognitive Impairment Exhibit Exacerbated Gait Slowing under Dual-Task Challenges
Current Alzheimer Research Reading and Writing the Blood-Brain Barrier: Relevance to Therapeutics
Recent Patents on CNS Drug Discovery (Discontinued) Persistent Hiccups as an Atypical Initial Presentation of COVID-19: A Case Report
Infectious Disorders - Drug Targets Tph2 Genetic Ablation Contributes to Senile Plaque Load and Astrogliosis in APP/PS1 Mice
Current Alzheimer Research Acetylcholinesterase Inhibition in Alzheimers Disease
Current Pharmaceutical Design Subjective Spatial Navigation Complaints - A Frequent Symptom Reported by Patients with Subjective Cognitive Decline, Mild Cognitive Impairment and Alzheimer's Disease
Current Alzheimer Research Can Transcriptomics Cut the Gordian Knot of Amyotrophic Lateral Sclerosis?
Current Genomics Functional Genomics Approach for Identification of Molecular Processes Underlying Neurodegenerative Disorders in Prion Diseases
Current Genomics Editorial [Hot topic: Polyunsaturated Fatty Acids and Human Health: A Critical Appraisal of the Evidence (Executive Editor: Antonio Cherubini)]
Current Pharmaceutical Design Prevalence of Neuropsychiatric Symptoms in Mild Cognitive Impairment and Alzheimers Disease, and its Relationship with Cognitive Impairment
Current Alzheimer Research Nanotechnology: A Novel Approach for Drug Development in Health Care System
Current Nanomaterials Antifungal Activity of 3-(heteroaryl-2-ylmethyl)thiazolidinone Derivatives
Medicinal Chemistry Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease
Current Neuropharmacology Alzheimer’s Disease and the Early Signs of Age-Related Macular Degeneration
Current Alzheimer Research Stroke as a Cause of Death in Death Certificates of Patients with Dementia: A Cohort Study from the Swedish Dementia Registry
Current Alzheimer Research Cellular Membrane Microparticles: Potential Targets of Combinational Therapy for Vascular Disease
Current Vascular Pharmacology Editorial (Hot Topic: Fragile X Families: A Lifespan Perspective)
Current Psychiatry Reviews